An Observational Study of the Real-life Management of Psoriasis Patients Treated With Otezla (Apremilast) in Belgium
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2018
Price : $35 *
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms OTELO
- Sponsors Celgene Corporation
- 04 Oct 2018 Planned End Date changed from 30 Jun 2018 to 31 Dec 2018.
- 04 Oct 2018 Planned primary completion date changed from 30 Jun 2018 to 31 Dec 2018.
- 04 Oct 2018 Status changed from recruiting to active, no longer recruiting.